SEC Filing Summary: Rexahn Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on May 5, 2009, regarding events occurring on May 4, 2009. The filing addresses the Company's status with the NYSE Amex LLC (formerly the American Stock Exchange) concerning compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin figures for the current period. However, it references the following financial conditions cited by the Exchange as reasons for non-compliance:
- Stockholder equity of less than $6 million.
- Losses from continued operations.
- Net losses in the five most recent fiscal years.
Specific debt and liquidity metrics are not disclosed in this document.
Material Changes and Listing Status
On February 24, 2009, the Company was notified of non-compliance with Section 1003(a)(iii) of the NYSE Amex Company Guide due to the financial conditions noted above. The Company submitted a compliance plan on March 23, 2009. On May 4, 2009, the Exchange accepted this plan, determining the Company made a reasonable demonstration of its ability to regain compliance.
Outlook, Risks, and Management Commentary
The Exchange has granted the Company an extension until August 24, 2010, to regain compliance with continued listing standards. The Company will be subject to periodic review by the Exchange staff during this extension period. A material risk identified is that failure to make progress consistent with the Plan within appropriate time periods could result in the Exchange staff initiating delisting proceedings.
Key Facts for Investor Verification
- Verify the Company's current stockholder equity and whether it remains below the $6 million threshold.
- Confirm the Company's progress against the milestones outlined in the compliance plan submitted on March 23, 2009.
- Monitor for any future notices from the Exchange regarding delisting proceedings if progress is not made by the August 24, 2010 deadline.
- Review the attached press release (Exhibit 99.1) for additional management commentary not included in the 8-K text.